The Ministry of Health is confident that contaminated batches of albumin, a blood product used in special medical circumstances, are not present in New Zealand.
The concern was raised after Australian blood supplier CSL Biotherapies detected traces of ethylene glycol in a number of batches of albumin.
Ministry of Health senior media advisor Kevin McCarthy said there was a failure in a tank used to regulate the temperature of albumin during the manufacturing process.
This allowed ethylene glycol, used in the casing of the tank, to leak into the albumin.
The fault was thought to have occurred between December last year and January 25, when the leak was discovered.
Mr McCarthy said he was "pretty confident it hasn't affected New Zealand''.